Persistence Rate With Subcutaneous Biologic Therapies in Patients With Ankylosing Spondylitis (As)
Value Health
.
2014 Nov;17(7):A384.
doi: 10.1016/j.jval.2014.08.2635.
Epub 2014 Oct 26.
Authors
M Govoni
1
,
R Lyu
2
,
Q Ding
3
,
T Fan
2
Affiliations
1
Merck Sharp & Dohme Limited, Rome, Italy.
2
Merck & Co., Inc, Whitehouse Station, NJ, USA.
3
Temple University, Philadelphia, PA, USA.
PMID:
27200867
DOI:
10.1016/j.jval.2014.08.2635
No abstract available